BioVentrix has announced a first-in-man milestone for its PliCath HF System following the completion of an epicardial catheter-based ventricular reconstruction in a 52-year-old male heart patient in Krakow, Poland.
BioVentrix’s PliCath HF System is designed to treat heart failure by reducing an enlarged left ventricle using a catheter.
The patient’s heart size decreased by 40% following surgery, and the volume of blood ejected from the ventricle after contraction increased by 15%.
Jerzy Sadowski, lead surgeon at Krakow’s Pope John Paul II Hospital, said the technology allowed the surgeons to perform the major reconstruction of the left ventricle in a matter of minutes and without incisions.
“This device has great promise and should help improve the quality of life of our patients suffering from heart failure,” he said.